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Invasive cancer of the uterine cervix is preventable when its
precursor lesions are detected and treated early. Cervical cytology
has been in use now for more than 50 years, and has proven itself
to be the main weapon of defence against this disease (Koss,
1989). However, in order to effectively protect the population
from cervical cancer, two keys elements must be in place – the
maximum number of adult women must be reached with the
screening test, and the quality and effectiveness of the test itself
must be unquestionable. 
The impact of cervical cytology screening has been demon-
strated by steadily reduced rates of incidence and mortality from
invasive cervical cancer in the developed countries over the last
decades (Stenkvist et al, 1984; Weidmann et al, 1998). In some
European countries, notably the Scandinavian countries, Great
Britain and the Netherlands, population screening programmes
have been organized. In others, such as France and the United
States, cytological screening has become a part of regular prevent-
ative care, primarily by educating and motivating individual
physicians and patients, with variations from country to country in
the coverage of the population and the frequency of testing
(Fender et al, 1998). In every country, increasing the participation
of women – particularly in the older age groups – in cervical
screening is a critical health policy goal (Fender et al, 1998;
Sancho-Garnier, 1998). 
Equally important as offering cervical screening to every
woman is ensuring that the test that is used is as accurate as
possible. In recent years, the accuracy of the conventional Pap
smear has come under a great deal of scrutiny. A recent meta-
analysis of the accuracy of the conventional Pap smear has
reported widely varying false negative rates (AHCPR, 1999).
Investigations into the sources of false negative errors have
concluded that the majority are due to sampling errors, that is, no
abnormal cells are found on the smeared slide upon review (Gay,
1985; AHCPR, 1999). Abnormal cells may also go undetected
because of poor smear quality (Weintraub, 1997). 
The liquid-based ThinPrep Pap Test was developed as a replace-
ment to the conventional method of preparing the cervical cyto-
logical specimen, and was approved for clinical use in the United
States in May, 1996. The sampling device(s) containing the
cervical cell sample from the patient is rinsed directly into a vial
containing PreservCyt (Cytyc Corporation, Boxborough, MA,
USA), a buffered preservative fluid; the vial is then sent to the
cytopathology laboratory for automated slide preparation using the
ThinPrep 2000 Processor (Cytyc Corporation, Boxborough, MA,
USA) (Linder and Zahniser, 1998). 
In clinical trials and routine clinical practice, the ThinPrep Pap
Test has been shown to be more effective than the conventional
Pap smear in several ways including significantly improved detec-
tion of low-grade and high-grade intraepithelial lesions, and a
significant improvement in specimen adequacy (Lee et al, 1997;
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This study, conducted in France, is the first formal multi-




6 laboratories in France participated in the study, each laboratory
obtaining cervical samples from 5 to 8 participating gynaeco-
logists and their patients. A total of 35 gynaecologists participated
in the study. 
Before the study commenced, the 6 laboratory directors (4
cytopathologists and 2 cytologists) and their participating staff
were trained to interpret ThinPrep slides, and also to use the
Bethesda System for reporting the screening results (Kurman and
Solomon, 1994). The study protocols and forms were reviewed
and approved by the local Ethics Committee. 
Patients were recruited sequentially in the participating gynae-
cologists’ practices, from March 1998 to September 1998.
According to the inclusion criteria, female patients aged 18 and
older, attending regular cervical cancer screening, and who volun-
tarily gave their informed consent, were enrolled in the study.
Patients were excluded from the study if they did not have a
uterine cervix, or if the cervix could not be visualized by the
clinician. 
Of the total of 5782 patients enrolled, 354 patients had to be
excluded from further analysis for logistical reasons: 338 patients
because clinicians made two slides for the conventional smear, and
16 patients for other reasons including lost slides (6), having been
entered twice (3), lacking a cervix (1) or being under 18 years of
age (6). This left 5428 qualified patients for whom there was one
conventional Pap smear and one ThinPrep slide for the initial
screening, thus fulfilling the statistical goal of 900 patients per
laboratory. 
Specimen collection and processing 
At the patient’s visit, the gynaecological examination was
performed in the usual way. For the cervical sample, a broom-style
collection device was used (Cervex Brush, Rovers B.V., Oss, The
Netherlands). A conventional Pap smear was made first, then the
remainder of the cellular material on the collection device was
rinsed into a vial containing PreservCyt preservative fluid (Cytyc
Corporation, Boxborough, MA, USA). The conventional Pap
smear, the vial, and the patient paperwork were forwarded to the
cytopathology laboratory where the ThinPrep 2000 device (Cytyc
Corporation, Boxborough, MA, USA) was used to prepare a slide
from the sample in the vial. This device automatically mixes the
sample, extracts a controlled number of cells onto a disposable
filter, and then transfers the cells to a glass slide. 
The screening protocol at each laboratory was organized so that
the conventional Pap smear and the ThinPrep slide from each
patient were screened routinely but separately; the cytologist
screening a slide was blinded to the diagnosis of the other slide
from the same patient. Once the initial screening had been
completed, the diagnoses obtained from the two slides for each
patient were correlated by a contract research organization
(Phoenix International France, Sèvres, France). All slide pairs with
discrepant diagnoses (n = 206), all concordant abnormal pairs
(ASCUS and higher; n = 101), plus a 5% random sample of the
concordant normal cases (n = 272) were sent to an independent
cytopathologist (C.M.) for review, again using a blinded protocol.
Discordant specimen adequacy was not used as a criteria for
review. After the independent review, the 6 investigators worked
as a panel to review the non-negative and non-concordant cases, as
well as any cases that had been upgraded by the independent
reviewer (total panel review n = 335). The panel review diagnosis
was determined by a majority decision. 
The results of the initial screening, the independent review, and
the panel review were tabulated and analysed by the contract
research organization. Three diagnoses were recorded. The
‘initial diagnosis’ was the diagnosis from the first reading of each
slide at the laboratory. The ‘final diagnosis’ for each slide was
defined as the diagnosis from the last reading performed (initial,
independent review or panel review) on that slide. The ‘reference
diagnosis’ was determined for each patient by comparing the final
diagnoses from both the ThinPrep and the conventional Pap slides
and recording the most abnormal of the two diagnoses for that
patient. 
Following the initial screening, 52 cases were excluded from the
data analysis because one or both of the slides was inadequate for
evaluation, leaving 5376 slides for the analysis of the initial
screening data. No attempt was made to make additional slides
from the vials of unsatisfactory ThinPrep cases. The independent
review determined one or both slides to be inadequate in 5 addi-
tional cases, leaving 5371 cases for the analysis of the reference
diagnoses. 
Statistical analysis 
For the statistical analysis, differences in the rates of disease
detection between the two preparation methods were assessed
statistically using McNemar’s test (2-category data) and the
Stewart-Maxwell test (3-category data). 
RESULTS 
Table 1 shows selected characteristics of the 6 participating labor-
atories and their patient populations. The volume of smears
processed annually by each laboratory varied from 4000 smears
per year to 200 000 smears per year. The patient populations were
fairly uniform across all 6 centres. The average age of patients was
41 years, and about 23% were post-menopausal. 
Table 2 shows the results of the initial, blinded routine-
screening of the conventional Pap smear and ThinPrep slide from
each patient. 50% more cases of LSIL were detected on the
ThinPrep slides (n = 99) than on the conventional smears (n =
66), and 18% more cases of HSIL (33 ThinPrep: 28 conventional
smear HSILs). For LSIL, HSIL, and cancers combined, there was
a statistically significant 39% increase in the detection
of LSIL and more severe lesions with the ThinPrep method
(P < 0.001). 
In the initial screening, 29% more ASCUS cases were detected
on the ThinPrep slides (n = 115) than on the conventional Pap
smears (n = 89). The ASCUS:SIL ratio was lower for the ThinPrep
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method (89:94 = 0.95:1); likewise, the ASCUS/AGUS:LSIL ratio
was lower for the ThinPrep method (116:99 = 1.17) than for the
conventional method (96:66 = 1.45). 
In this study, the cytological diagnoses were verified by a two-
stage pathologist review process, as described above. Pursuant to
this review, there were 145 cases that were assigned a reference
diagnosis of LSIL or higher (LSIL+). Table 3a shows the correla-
tion of the two initial cytological diagnoses from the 145 cases
with confirmed LSIL+ cytology. The ThinPrep initial diagnosis
was LSIL+ in 69% of these cases (100/145); this was 18% higher
than the proportion of conventional Pap smears originally dia-
gnosed as LSIL+ (85/145 = 59%; P = 0.041). A similar analysis,
this time for the 230 cases where the reference diagnosis was
ASCUS and higher (ASCUS+), also showed a significantly
higher rate of detection with the ThinPrep method (190/130 =
83%) than with the conventional smear method (151/230 = 66%;
P < 0.001). 
Specimen adequacy results from the initial screening are
summarized in Table 4. The proportion of ‘satisfactory (SAT)’
slides was slightly higher for conventional Pap smear slides (91%)
than for the ThinPrep slides (87%). The underlying reasons for
which slides prepared by the two different methods were deemed
to be ‘unsatisfactory (UNSAT)’ or ‘satisfactory but limited by
(SBLB)...’ were distinctly different. There were more conven-
tional smears than ThinPrep slides that were ‘limited by’
obscuring blood (110 vs. 3 cases), obscuring inflammation (37 vs.
11 cases), thickness of cells (20 vs. 0 cases), and air drying (10 vs.
1 cases). There were more ThinPrep slides than conventional
smears that were ‘limited by’ a lack of endocervical component
(642 vs. 315 cases). 
DISCUSSION 
This study, the first formal multi-laboratory, large-scale evalua-
tion of the ThinPrep fluid-based cervical cytological method in
Europe, comes at a time when policies for women’s health care
and technological advances in cervical cytology are both devel-
oping rapidly in Europe. The goal of maximizing the participation
of all adult women in cervical screening is being realized to
varying degrees in different countries (Fender et al, 1998). In
Europe, a screening frequency of about every 3 years is the stand-
ard (Stenkvist et al, 1984; Fender et al, 1998). Given the evidence
that false negative rates for the conventional Pap smear are higher
than they were once thought to be, a method that significantly
increases the accuracy of the smear test at an incremental cost for
a single test may be more cost effective than the alternative which
is to screen every woman at more frequent intervals in order to
catch the missed positive cases before they progress to cancer. 
In this study, significantly more precancerous lesions were
detected on slides prepared using the ThinPrep preparation method
than on conventional Pap smear slides made first from the same
cellular sample. 50% more LSIL lesions and 18% more HSIL
lesions were detected in routine screening; taking LSIL and higher
lesions together, there was a significant, 39% increase in detection
with the ThinPrep method (P < 0.001). Numerous other recent
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Table 2 Results of initial screening, ThinPrep versus Conventional Pap test diagnoses, by Bathesda diagnosis categoriesa
Conventional Pap test 
Negative ASCUS AGUS LSIL HSIL SQ CA GL CA Total 
Negative 5069 40 5 9 4 0 0 5127 
ThinPrep ASCUS 73 32 1 7 2 0 0 115 
Pap test AGUS 0 0 1 0 0 0 0 1 
LSIL 38 14 0 46 1 0 0 99 
HSIL 4 3 0 4 21 1 0 33 
SQ CA 0 0 0 0 0 0 0 0 
GL CA 0 0 0 0 0 0 1 1 
Total 5184 89 7 66 28 1 1 5376 
aBethesda category abbreviations used: ASCUS – Atypical squamous cells of undetermined significance.  AGUS – Atypical glandular cells of undetermined
significance.  LSIL – Low-grade squamous intraepithelial lesion.  HSIL – High-grade squamous intraepithelial lesion.  SQ CA – Squamous cell carcinoma.  
GL CA – Glandular cell carcinoma.
Table 1 Characteristics of the six participating laboratories and their patient populations 
Centre Laboratory volume   Number of  Number of ‘per  Mean patient   Post- Previous Previous Abnormal
of Papanicolaou participating  protocol’ patientsa age (SD) menopausal abnormal LSIL+ (%) this study
smears per year gynaecologists patients (%) Papanicolaou smears (%) LSIL + (%)
A 200000 8 906 41 (12.8) 23.1% 8.7% 5.2% 2.0% 
B 20000 6 906 38 (11.8) 16.4% 11.3% 8.6% 2.1% 
C 56773 5 909 40 (12.8) 22.7% 14.2% 5.9% 1.2% 
D 100000 5 908 42 (12.7) 25.4% 8.8% 7.3% 1.8% 
E 4000 5 899 40 (12.6) 22.9% 13.1% 5.1% 1.1% 
F 70000 6 900 44 (13.2) 28.2% 13.8% 10.6% 1.2% 
Total N/A 35 5428 41 (12.8) 23.1% 11.6% 7.1% 1.6% 
aAll patients who meet the inclusion/ exclusion criteria, with available pair of slides. bAbnormal Papanicolaou smear in the patient’s previous medical history. c
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studies concur unanimously that the ThinPrep method yields signif-
icantly higher detection of SIL lesions (Lee et al, 1997; Roberts
et al, 1997; Bolick and Hellman, 1998; Corkill et al, 1998; Dupree
et al, 1998; Papillo et al, 1998; Carpenter and Davey, 1999; Diaz-
Rosario and Kabawat 1999; Guidos and Selvaggi, 1999; Wang
et al, 1999; Yeoh et al, 1999; Weintraub and Morabia 2000). 
Because this was the first multi-laboratory evaluation of the
ThinPrep method in Europe, the study protocol was designed to be
similar to that used for the clinical trial study in the USA,
including the broom type collection device, a split sample from
each subject, blinded screening, and independent pathologist
review (Lee et al, 1997). The diagnosis results of this study were
Table 4 Specimen adequacy on initial diagnosis: comparison of conventional and ThinPrep slides 
Specimen adequacy evaluation Conventional ThinPrep 
N% N %  
Number of patients 5428 100.00 5428 100.00 
Satisfactory for evaluation (SAT) 4914 90.53 4726 87.07 
Satisfactory for evaluation but limited by (SBLB): 488 8.99 673 12.40 
Air drying artifact 10 0.18 1 0.02 
Thick smear 20 0.37 0 0.00 
Cylindrical endocervical cells or squamous metaplasia absent 315 5.80 642 11.83a
Squamous epithelial cells scanly 29 0.53 21 0.39 
Obscuring blood 110 2.03 3 0.06a
Obscuring inflammation 37 0.68 11 0.20a
No cells 1 0.02 1 0.02 
Cytolysis 6 0.11 3 0.06 
Other 3 0.06 1 0.02 
Unsatisfactory for evaluation (UNSAT): 26 0.48 29 0.53 
Air drying artifact 0 0.00 0 0.00 
Thick smear 0 0.00 0 0.00 
Cylindrical endocervical cells or squamous metaplasia absent 5 0.09 11 0.20 
Squamous epithelial cells scanty 4 0.07 19 0.35 
Obscuring blood 19 0.35 5 0.09 
Obscuring inflammation 7 0.13 0 0.00 
No cells 0 0.00 4 0.07 
Cytolysis 2 0.04 1 0.02 
Other 0 0.00 1 0.02 
Stewart-Maxwell test for the 3 major categories of SAT, SBLB, UNSAT: P < 0.001. aMcNemar test, P < 0.001. NOTE: Within the SBLB and UNSAT categories, a
slide may have more than one factor. 
Table 3 Cases with non-negative reference diagnosesa: correlation of initial ThinPrep and conventional diagnoses 
a: Cases with reference diagnosis of LSIL and higher: ThinPrep versus conventional initial diagnoses 
Conventional Pap test 
Negative/ASCUS/AGUS LSIL+ Total 
ThinPrep Negative/ASCUS/AGUS 29 16 45 
Pap test LSIL+ 31 69 100 
Total 60 85 145 
McNemar’s test P value = 0.041. Reference diagnosis LSIL+ cases initially detected with ThinPrep Pap test = 100/145 =
69.0%. Reference diagnosis LSIL+ cases initially detected with Conventional Pap test = 85/145 = 58.6%. Ratio of TP/CP
confirmed positive initial diagnoses = 100/85 = 1.18. aNote: Reference diagnosis after expert/ panel review of all cases
with non-negative initial diagnosis plus 5% of concordant negative cases. 
b: Cases with reference diagnosis of ASCUS/AGUS and higher: ThinPrep versus conventional initial diagnosis 
Conventional Pap test 
Negative ASCUS/AGUS+ Total 
ThinPrep Negative 13 27 40 
Pap test ASCUS/AGUS+ 66 124 190 
Total 79 151 230 
McNemar’s test P value < 0.001. Reference diagnosis ASCUS+ cases initially detected with ThinPrep Pap test = 190/230
= 82.6%. Reference diagnosis ASCUS+ cases initially detected with Conventional Pap test = 151/230 = 65.7%. Ratio of
TP/CP confirmed positive initial diagnoses = 190/151 = 1.26. 364 J Monsonego et al
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similar to those from the US clinical trial study: 18% increase in
LSIL+ initial diagnoses (P < 0.001), confirmed by independent
pathologist review. 
Since this study was designed, the ThinPrep method has been
widely adopted into routine clinical practice elsewhere, with the
cervical sample collected directly to the vial, rather than split
between two methods as was done in this study. There have been 4
studies in which cervical cytology from practices that have
converted 100% to direct-to-vial, routine clinical use of the
ThinPrep method have been compared to the performance of the
conventional Pap smear method from the same physicians’ prac-
tices one year prior to ThinPrep conversion (Dupree et al, 1998;
Papillo et al, 1998; Carpenter and Davey, 1999; Diaz-Rosario and
Kabawat, 1999). Taken together, these direct-to-vial studies
showed more markedly improved screening results than this split-
sample study did: significant average increases of 66% in LSIL
detection (P < 0.001) and 57% in HSIL detection (P < 0.001), and
a decrease in ASCUS diagnoses of 32% (P < 0.001). 
In this study, the accuracy of the initial cytological screening
was evaluated cytologically, using expert pathologist reviews.
Since there was no way of assessing the competence of the 35
investigating gynaecologists in performing colposcopic biopsies,
the accuracy of these examinations would have been difficult to
interpret because of the expected variability of the results (Sellors
et al, 1990; Hopman et al, 1995). For the 145 cases with reference
(confirmed) diagnoses of LSIL and higher, there was an 18%
higher rate of detection of LSIL+ on the initial diagnosis with the
ThinPrep method (P = 0.041). Histological verification of the
cytological diagnoses in patients diagnosed with abnormalities
was not performed in this study. The reason is that for routine
cervical screening populations, subjecting every patient with a
non-negative diagnosis to colposcopy and biopsy would be nei-
ther practical nor cost-effective. There have however, been 
data published from four direct-to-vial studies in which
cytology–histology correlation was made (Papillo et al, 1998;
Carpenter and Davey, 1999; Diaz-Rosario and Kabawat, 1999;
Guidos and Selvaggi, 1999). When the data are combined, the
positive predictive value (PPV) of an LSIL diagnosis is found to
be 76%, equal for both the ThinPrep method and the conventional
smear method. For HSIL lesions, the PPV was 88% for ThinPrep
and 90% for the conventional smear; for LSIL and HSIL together,
the PPV was 80% for both methods (Papillo et al, 1998; Carpenter
and Davey, 1999; Diaz-Rosario and Kabawat, 1999; Guidos and
Selvaggi, 1999). This finding, that the positive predictive value of
a SIL diagnosis is maintained when the ThinPrep method is used,
means that the significant increases in SIL cytology diagnoses that
have been documented for the ThinPrep method indicate a true
increase in the detection of biopsy-confirmable disease. 
In this study, 30% more cases of ASCUS were diagnosed with
ThinPrep than on conventional smears. While in agreement with
one other split-sample study (Corkill et al, 1998) and several
studies in which different groups of physicians and patients were
used for the test and control groups (Bolick and Hellman, 1998;
Guidos and Selvaggi, 1999; Weintraub and Morabia, 2000), this
finding is in contradiction with the US clinical trial study and most
of the direct-to-vial studies published to date (Lee et al, 1997;
Dupree et al, 1998; Papillo et al, 1998; Carpenter and Davey, 1999;
Diaz-Rosario and Kabawat, 1999; Wang et al, 1999; Yeoh et al,
1999). It is difficult to interpret what this finding means. ASCUS
is not a commonly used diagnostic category in the French cytology
setting – both the Bethesda categorization and the slightly different
visual characteristics of ThinPrep cytology were new to the cyto-
logists and pathologists in this study. The laboratory directors
received a one-week training in the use of the ThinPrep technique.
With the exception of one centre which did have extensive experi-
ence with liquid-based cytology, none of the others had much, if
any, experience with this method. In other ThinPrep studies, the
number of ASCUS diagnoses has sometimes been found to
increase (Bolick and Hellman, 1998; Corkill et al, 1998), and
sometimes to decrease (Papillo et al, 1998; Wang et al, 1999), with
the ThinPrep method. It is nevertheless accepted that with
increasing experience with the ThinPrep method, the number of
ASCUS cases decreases. At the same time, the ASCUS:LSIL
ratio, an overall indicator of screening performance, was reduced
with the ThinPrep method from 1.45;1 to 1.17:1. Both ratios were
well within the range of good cytological practice, indicating that
ASCUS was, not being over-diagnosed (Bolick and Hellman,
1998; Corkill et al, 1998; Dupree et al, 1998; Papillo et al, 1998;
Carpenter and Davey, 1999; Diaz-Rosario and Kabawat, 
1999; Guidos and Selvaggi, 1999; Wang et al, 1999; Yeoh et al, 1999;
Weintraub and Morabia, 2000). The detection of ASCUS smears
can however have an impact on public health. The evidence from
biopsy review studies underscores the importance of ASCUS
cytology in overall detection of high-grade lesions. Statistically,
only 7% of individual patients with ASCUS cytology are found to
have a high-grade lesion (Kinney et al, 1998) but looked at from
the screening population, and because the prevalence of the
ASCUS category of smears is higher than others (LSIL/HSIL), it
has been shown that about 40% of histologically confirmed HSIL
were preceded by an ASCUS cytological diagnosis (Kinney et al,
1998). 
As has been found in other studies, the number of slides that
were ‘satisfactory but limited by...’ obscuring blood, inflamma-
tion, thickness, and air drying, was much lower for the slides
prepared by the ThinPrep method. In this study, there were more
ThinPrep than conventional slides that lacked endocervical
component. This result has been noted in other split-sample
studies (Lee et al, 1997; Wang et al, 1999); the first portion of the
sample was used to make the conventional smear and may have
contained most of the endocervical component. Another factor
may have been the necessity of introducing the ‘broom’ sampling
device for this study. The spatula-endocervical brush combination
might have yielded a higher proportion of samples with endocer-
vical component. In every other published performance study of
the ThinPrep 2000 device, particularly the direct-to-vial studies,
there has been an improvement in smear adequacy – increased
SAT cases and decreased SBLB cases – with the ThinPrep prepa-
ration method (Lee et al, 1997; Bolick and Hellman, 1998; Papillo
et al, 1998; Carpenter and Davey, 1999; Diaz-Rosario and
Kabawat, 1999; Guidos and Selvaggi, 1999; Wang et al, 1999;
Yeoh et al, 1999; Weintraub and Morabia, 2000). 
Cost-effectiveness studies of this new technology have been
published, and are ongoing (AHCPR 1999; Brown and Garper,
1999; Hutchinson, 2000). In Great Britain, the National Institute
for Clinical Excellence (NICE) of the National Health Service
(NHS) has begun an appraisal of liquid-based cytology for cervical
screening, which is scheduled to be published in 2000 (NICE,
2000a,b). The costs of the new technology will include the equip-
ment cost of the ThinPrep 2000 device (at the laboratory), and the
per test incremental cost of the disposable vial, the filter cylinder,
and processing. Weighed against these will be the benefits of
significantly increased screening accuracy and adequacy – lesspatient recalls for inadequate or inconclusive sampling, and the
maintenance of the 3-year screening interval due to significantly
less missed positives. Higher rates of early disease detection will
decrease the number of costly and severe treatments needed for
late stage, invasive, or fatal disease. 
Another potential benefit of the ThinPrep preparation method is
that the remainder of the cell sample in the vial can be used for
adjunctive testing (HPV and other diseases), without requiring the
patient to be recalled (Sherman et al, 1997). HPV testing may be a
promising way to more accurately recognize underlying signific-
ant disease in patients with atypical and low-grade cytology find-
ings (Manos et al, 1999), and also in conjunction with cytology a
useful screening tool.
In conclusion, this and other studies of the ThinPrep Pap Test
show that this new technology significantly increases the detection
of squamous intraepithelial lesions of the cervix. In routine use,
when the entire sample is put into the vial, SIL detection and spe-
cimen adequacy are improved at higher rates than the results of
this split-sample study. The ThinPrep Pap Test is strongly in the
best interests of public health – by improving the quality of the
sample and reducing the likelihood of false negative cytology
results, it will significantly improve early detection and treatment
of cervical abnormalities without dictating a change in screening
intervals. 
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